Prevalence of painful and painless diabetic peripheral neuropathy in the Northern Danish Region: A population-based study.
北丹麥地區糖尿病周邊神經病變的疼痛性與無疼痛性流行率:一項基於人群的研究。
Prim Care Diabetes 2024-08-31
The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice.
GLP-1 藥物 semaglutide 和 tirzepatide 不會改變 5XFAD 和 APP/PS1 小鼠的疾病相關病理、行為或認知功能。
Mol Metab 2024-08-31
Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.
GLP1-RA 在優化減重後的減肥手術中的角色:系統性回顧與統合分析。
Obes Surg 2024-08-31
Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese Participants.
健康的日本人和非日本人參與者中Cilofexor和Firsocostat的藥物代謝動力學及安全性。
J Clin Pharmacol 2024-08-30
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
Liraglutide、Tirzepatide 和 Retatrutide 對 db/db 小鼠糖尿病腎病的影響比較。
Endocrine 2024-08-30
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
2型糖尿病中慢性腎病嚴重程度對semaglutide心血管結果的影響:FLOW試驗。
Eur Heart J 2024-08-30
Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.
Semaglutide 改善冠狀動脈疾病大型動物模型中的心肌灌注和心臟功能。
bioRxiv 2024-08-30